Strong Revenue Growth
KORU Medical Systems reported revenue exceeding $10 million for the second consecutive quarter, with a year-over-year growth of 27%.
Core Business Performance
The core subcutaneous immunoglobulin (SCIG) business grew 30%, driven by international expansion and strong patient growth.
International Market Expansion
International revenue grew by 230%, with significant contributions from European markets due to conversions to prefilled syringes.
Oncology Infusion Study Success
Completed a successful US-based oncology study with high nurse and patient satisfaction, validating Core's value proposition in the oncology market.
Increased Revenue Guidance
Raised full-year revenue guidance to $40,500,000 to $41,000,000, representing 20% to 22% growth.
Positive Financial Metrics
Achieved positive adjusted EBITDA, with gross profit growth of 21% year-over-year, and generated positive cash flow.